Combination therapy for advanced colorectal cancer
Part of Cancer clinical trials.
This trial tests a new drug (IBI363) combined with either bevacizumab or furuitinib for people with advanced colorectal cancer that has worsened after standard treatments. It aims to find a more effective option for those who have limited alternatives.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colorectal cancer that has been confirmed by a biopsy.
- You have tried standard treatments or are not able to take them.
- You are between 18 and 75 years old.
- You are in generally good health (able to care for yourself and up and about).
- You have at least one tumor that can be measured on scans.
- You agree to use effective birth control during the study and for 6 months after treatment ends.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called IBI363 for people with advanced cancer that has not responded to other treatments. It aims to see if the drug can help shrink tumors or slow cancer growth.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a different way of giving a chemotherapy drug called irinotecan, along with two other drugs (5-FU and bevacizumab), for people whose cancer got worse after first-line treatment. It aims to see if this combination can help control the cancer.
This study tests a new combination treatment for advanced colorectal cancer that has stopped responding to standard treatments or is newly diagnosed. It aims to see if the combination can shrink tumors or slow their growth.
This study tests a combination of two drugs (bevacizumab and adebrelimab) for people with a specific type of advanced colorectal cancer that has not responded to standard treatments. It aims to see if this combination can help control the cancer and improve outcomes.
Hear when a new Advanced Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.